Replies to post #48496 on Predictive Technology Group Inc (PRED)

[zugisland]

quick takeaway..read very fast thru.
1) There is a Saliva test using TMO ..I could not tell or see if any revenues were generated in the period from this test which has a EUA.
2_ Deloitte is still auditor
3) Cash on hand was about 350000 in cash which does not reflect the remainder of the 3 mill loan.
4) Looks like they passed on the 5 million to the Chinese from Wellgistics.Wellgitics wants money back but Pred says that it was non refundable and that Well didnt pay for the rest of the order thus loosing Wellgistics exclusivity for a test which still has a "pending " Eua .
5) Yr end sales were 24 million . Will check later what that meant in terms of 4th Q

So obviously the Saliva test is real and a real hope that will result in revs asap. Also it does have an EUA already too.This are huge positives..Anthazar what am i missing ?

[patience_in_waiting]

10K is light on notes and subsequent events from the July- September time frame, which could have tipped PRED’s hand in terms of what is to come.

Obviously that’s intentional, and part of the game plan to get off the grey market.

[IB_]

So PRED borrowed money from another company to pay Deloitte, what is there to be excited about with that BS, Merle ?????????????????????????

If PRED has two nickels to rub together, they found them on the sidewalk and will likely lose them both in a lawsuit !!!!!!!!!!!!!!!!!!!!!!!

PRED is a POS investment,

IB_

[zugisland]

Anthazar you made a claim a few weeks ago that the subsequent events in the filing would contain some potent good news. Care to elaborate. ?

[buzzard1147]

Ant..Good sleuthing.

[zugisland]

anthazar this is all that is listed under subsequent events.
" July and August, the Company issued promissory notes to an accredited investor in the amount of $1,000,000. The notes bear interest at 15% per annum and mature on September 21, 2020. The notes are secured by the revenues arising from the Company's Assurance VR™ COVID-19 RT-PCR test.



On September 25, 2020, the Company and the same accredited investor amended and restated the outstanding notes and increased the principal amount by $2,000,000 to a total of $3,000,000. The amended promissory note bears 15% simple interest. No payments on the amended promissory note are due until September 2021, at which time monthly payments equal to 1/36th of the outstanding principal and interest amount shall commence. Interest accruing prior to September 2021 will be added to the principal amount. Any remaining principal and interest shall be due on September 30, 2022. The amended promissory note is secured by the revenues arising from the Company's Assurance VR™ COVID-19 RT-PCR test and may be prepaid without penalty.



The Company entered into a Consulting Agreement with the accredited investor on the same date that the promissory notes were amended. The Company will provide various services in connection with the accredited investor's COVID-19 testing business, including technical consultation and sales lead generation. The Company may earn up to $1,000,000 in milestone payments and shall earn a commission of 5% of the accredited investor's sales generated from sales leads provided by the Company. Amounts earned under the Consulting Agreement shall first be applied to any balance outstanding under the amended promissory notes. The Company's total compensation under the Consulting Agreement is capped at $4,000,000. The agreement may be cancelled by the accredited investor without penalty.

-92-

[PRED2020]

Just think what they could of done with H&R block for half the cost!

[reverse_long]

great use of 500k for a rapidly money losing company huh? Priorities!!